genom
contain
genet
epigenet
inform
genom
provid
blueprint
manufactur
protein
requir
creat
live
thing
epigenet
inform
provid
instruct
genet
inform
use
robertson
major
form
epigenet
inform
within
dna
molecul
mammalian
cell
dna
methyl
coval
addit
methyl
group
cytosin
mostli
within
cpg
dinucleotid
somat
cell
robertson
dna
methyl
involv
control
gene
express
regul
parent
imprint
stabil
x
chromosom
inactiv
well
mainten
genom
integr
also
implic
develop
immun
system
cellular
reprogram
brain
function
behavior
jurkowska
et
al
dna
methyl
mediat
famili
dna
methyltransferas
enzym
dnmt
mammal
three
dnmt
identifi
far
human
genom
includ
two
de
novo
methyltransferas
mainten
methyltransferas
gener
abund
activ
three
robertson
yokochi
robertson
goll
bestor
respons
duplic
pattern
dna
methyl
replic
essenti
mammalian
develop
cancer
cell
growth
chen
et
al
enzym
key
regul
gene
transcript
role
carcinogenesi
subject
consider
interest
past
decad
robertson
jone
baylin
therefor
specif
inhibit
dna
methyl
attract
novel
approach
cancer
therapi
robertson
lyko
brown
kelli
et
al
portela
estel
dna
methyl
inhibitor
also
emerg
promis
strategi
treatment
immunodefici
brain
disord
zawia
et
al
miller
et
al
human
protein
amino
acid
whose
structur
divid
ntermin
regulatori
domain
ctermin
catalyt
domain
cheng
blumenth
lan
et
al
jurkowska
et
al
mechan
dna
methyl
schemat
depict
fig
vilkaiti
et
al
schermelleh
et
al
sippl
jung
dnmt
form
complex
dna
cytosin
methyl
flip
dna
thiol
catalyt
cystein
act
nucleophil
attack
target
cytosin
gener
coval
intermedi
cytosin
activ
conduct
nucleophil
attack
cofactor
sadenosyllmethionin
adometsam
form
coval
adduct
sadenosyllhomocystein
adohcysah
attack
assist
transient
proton
cytosin
ring
endocycl
nitrogen
atom
stabil
glutam
residu
arginin
residu
may
particip
stabil
intermedi
make
hydrogen
bond
interact
carbonyl
oxygen
cytosin
coval
complex
methyl
base
dna
resolv
deproton
gener
methyl
cytosin
free
enzym
structur
mammalian
dnmt
divid
two
major
part
larg
ntermin
regulatori
domain
variabl
size
regulatori
function
ctermin
catalyt
domain
conserv
eukaryot
prokaryot
dnmt
fig
ntermin
domain
guid
nuclear
local
enzym
mediat
interact
protein
dna
chromatin
smaller
ctermin
domain
harbor
activ
center
enzym
contain
amino
acid
motif
diagnost
dnmt
jurkowska
et
al
catalyt
domain
core
structur
share
dnmt
core
structur
term
adometdepend
mtase
fold
consist
sixstrand
parallel
b
sheet
seventh
strand
insert
parallel
fashion
fifth
sixth
strand
six
helic
fold
around
central
b
sheet
motif
x
domain
involv
cofactor
bind
motif
iv
vi
viii
involv
catalysi
target
recognit
domain
trd
nonconserv
region
motif
viii
ix
involv
dna
recognit
specif
fig
jeltsch
jurkowska
et
al
threedimension
structur
inform
human
limit
recent
crystal
structur
human
bound
duplex
dna
contain
unmethyl
cytosineguanin
cg
site
publish
song
et
al
howev
conform
crystal
structur
inact
state
target
base
dna
flip
geometri
catalyt
site
reflect
catalyt
mechan
detail
structur
dnmt
avail
crystal
structur
dnmt
extens
review
elsewher
cheng
blumenth
sippl
jung
lan
et
al
dna
methyl
inhibitor
well
character
test
clinic
trial
issa
kantarjian
date
deoxycytidin
decitabin
develop
clinic
two
drug
nucleosid
analogu
incorpor
dna
caus
coval
trap
subsequ
deplet
dnmt
schermelleh
et
al
stresemann
lyko
aza
nucleosid
approv
food
drug
administr
unit
state
treatment
myelodysplast
syndrom
demonstr
signific
although
usual
transient
improv
patient
surviv
current
test
mani
solid
cancer
schrump
et
al
howev
aza
nucleosid
rel
low
specif
character
substanti
cellular
clinic
toxic
stresemann
lyko
exact
mechan
antitumor
action
also
remain
unclear
issa
palii
et
al
fandi
et
al
consequ
clear
need
identifi
novel
specif
dnmt
inhibitor
function
via
incorpor
dna
increas
number
substanc
report
inhibit
dnmt
lyko
brown
compound
see
identifi
use
virtual
screen
siedlecki
et
al
kuck
et
al
other
approv
drug
indic
hydralazin
procain
procainamid
compound
sever
natur
product
implic
dna
methyl
inhibit
extens
review
elsewher
hauser
jung
gilbert
liu
li
tollefsbol
medinafranco
caulfield
molecular
dock
pharmacophor
model
molecular
dynam
md
comput
approach
research
group
use
explor
ligandbind
interact
dnmt
inhibitor
evan
bronowska
caulfield
medinafranco
medinafranco
caulfield
yoo
medinafranco
c
due
absenc
crystallograph
structur
human
publish
recent
song
et
al
molecular
model
studi
catalyt
bind
site
dnmt
conduct
use
homolog
model
herein
describ
dock
studi
known
inhibitor
catalyt
site
recent
publish
crystal
structur
song
et
al
prior
dock
conform
catalyt
site
model
activ
conform
use
md
knowledg
first
molecular
model
studi
conduct
catalyt
bind
site
crystal
structur
human
base
dock
result
develop
structurebas
pharmacophor
model
inhibitor
effort
identifi
novel
nonnucleosid
inhibitor
also
report
experiment
activ
aurintricarboxyl
acid
ata
show
submicromolar
inhibit
molecular
model
studi
ata
catalyt
site
crystal
structur
also
discuss
recent
publish
xray
crystal
structur
human
correspond
enzym
bound
dnacontain
unmethyl
cpg
site
structur
catalyt
loop
open
conform
catalyt
cystein
far
away
bind
site
therefor
geometri
catalyt
site
crystal
structur
repres
activ
conform
enzym
correspond
catalyt
mechan
dna
methyl
contrast
xray
structur
bacteri
mhhai
klimasauska
et
al
kumar
et
al
previous
develop
homolog
model
yoo
medinafranco
dna
embed
catalyt
core
catalyt
loop
also
close
insert
target
cytosin
activ
site
fig
therefor
use
md
model
crystal
structur
human
activ
state
end
crystal
structur
complex
bound
adohci
obtain
protein
data
bank
pdb
code
unmethyl
dna
domain
except
methyltransferas
domain
remov
dna
doubl
helix
reconstruct
structur
mhhai
pdb
klimasauska
et
al
catalyt
core
target
cytosin
insert
activ
site
miss
residu
model
use
prime
version
llc
new
york
ny
refin
model
treat
accord
protein
prepar
wizard
implement
maestro
optim
hbond
network
flip
orientationstautomer
state
gln
asn
residu
perform
geometri
optim
maximum
root
mean
squar
deviat
rmsd
forc
field
recent
employ
similar
procedur
prepar
structur
protein
et
al
stabil
refin
model
probe
md
simul
use
macromodel
version
llc
new
york
ny
stochast
dynam
sd
method
use
opl
forc
field
implicit
water
solvat
follow
condit
equilibr
time
ps
k
b
ps
simul
time
k
c
time
step
fs
conform
store
make
direct
comparison
energi
conform
obtain
sd
collect
sd
conform
submit
multiminim
step
polakribier
conjug
gradient
prcg
converg
sd
simul
judg
complet
rmsd
store
structur
interact
key
amino
acid
residu
target
cytosin
figur
show
conform
modifi
xray
structur
catalyt
loop
activ
conform
although
rmsd
ca
atom
initi
modifi
xray
structur
catalyt
loop
modifi
structur
adopt
differ
conform
respect
xray
structur
xray
structur
distanc
superimpos
target
cytosin
sulfur
atom
catalyt
loop
fig
contrast
catalyt
loop
modifi
structur
locat
cytosin
activ
site
lid
target
cytosin
lie
nucleophil
sulfur
atom
adohci
distanc
cytosin
sulfur
atom
cytosin
atom
away
sulfur
atom
adohci
addit
proton
form
cytosin
make
hydrogen
bond
acid
side
chain
fig
aphosph
backbon
deoxycytidin
make
hydrogen
bond
network
addit
oh
sugar
moieti
form
hydrogen
bond
interestingli
key
interact
env
motif
rxr
motif
catalyt
loop
observ
homolog
model
yoo
medinafranco
catalyt
core
modifi
crystal
structur
homolog
model
yoo
medinafranco
similar
conform
catalyt
loop
insight
suggest
modifi
structur
homolog
model
reliabl
explor
bind
mode
inhibitor
human
key
amino
acid
residu
modifi
crystal
structur
carbon
atom
gray
crystal
structur
carbon
atom
pink
hydrogen
bond
interact
depict
dash
dock
known
activ
dnmt
inhibitor
homolog
model
publish
yoo
medinafranco
studi
bind
mode
inhibitor
except
ata
compar
first
time
use
molecular
model
protocol
despit
fact
inhibitor
differ
structur
scaffold
compound
studi
show
common
interact
key
amino
acid
residu
addit
insight
molecular
dock
support
propos
mechan
inhibit
compound
curcumin
parthenolid
put
coval
blocker
catalyt
site
yoo
medinafranco
build
previou
work
perform
dock
establish
inhibitor
catalyt
site
xray
structur
modifi
activ
conform
see
previou
section
refer
neg
control
also
dock
compound
previous
shown
weak
enzymat
inhibitori
activ
use
decoy
siedlecki
et
al
kuck
et
al
chemic
structur
group
compound
shown
fig
worth
note
compound
fig
screen
experiment
condit
therefor
quantit
comparison
dock
score
enzymat
inhibit
feasibl
howev
possibl
assess
whether
molecular
dock
abl
separ
activ
inact
decoy
also
importantli
case
seek
explor
put
bind
site
establish
inhibitor
catalyt
bind
site
use
crystallograph
structur
conduct
dock
chemic
structur
compound
built
maestro
llc
new
york
ny
minim
forc
field
gradient
termin
macromodel
ligand
prepar
conform
search
macromodel
ligprep
version
llc
new
york
ny
gener
possibl
configur
ligprep
conform
analysi
carri
mont
carlo
multipl
minimum
lowmod
conform
search
method
employ
opl
forc
field
use
gbsa
water
solvat
model
lowest
energi
conform
ligand
dock
xray
structur
modifi
activ
conform
see
use
program
glide
version
llc
new
york
ny
group
success
use
glide
develop
bind
model
inhibitor
dnmt
kuck
et
al
b
caulfield
medinafranco
fig
compound
consid
studi
previous
test
inhibit
activ
b
inactivedecoy
yoo
medinafranco
c
three
flexibl
dock
method
includ
highthroughput
virtual
screen
htv
standard
precis
sp
extra
precis
xp
implement
glide
use
comparison
method
receptor
grid
box
side
default
inner
box
center
target
cytosin
input
partial
charg
use
constrain
appli
dock
case
htv
sp
dock
method
one
pose
per
ligand
intend
larg
databas
screen
applic
pose
per
ligand
xp
dock
method
set
optim
precis
pose
topscor
ligand
htv
sp
dock
postdock
minim
appli
investig
effect
accuraci
three
dock
protocol
five
dock
pose
per
ligand
minim
htv
sp
pose
per
ligand
xp
best
dock
pose
xp
dock
select
gener
pharmacophor
featur
see
tabl
summar
result
dock
catalyt
site
crystal
structur
use
glide
htv
sp
xp
comparison
dock
score
obtain
use
previous
report
homolog
model
yoo
medinafranco
shown
dock
result
abl
predict
energet
favor
bind
mode
accur
score
dock
conform
dock
result
glide
htv
sp
modifi
crystal
structur
homolog
model
show
signific
impact
rank
score
remark
consist
shown
graph
tabl
dock
result
htv
sp
rank
activ
inact
similar
variat
almost
activ
compound
stabl
energi
valu
inact
note
known
inhibitor
except
procain
procainamid
rank
higher
decoy
nucleosid
inhibitor
includ
decitabin
show
best
glide
xp
dock
score
use
modifi
crystallograph
homolog
model
clear
studi
optim
dock
score
combin
decreas
number
fals
posit
fals
neg
virtual
screen
figur
show
correspond
bind
mode
select
dnmt
inhibitor
gener
glide
xp
catalyt
bind
site
modifi
crystal
structur
bind
mode
nucleosid
inhibitor
close
match
target
cytidin
aphosph
zebularin
make
hydrogen
bond
network
catalyt
loop
trd
ribos
group
form
addit
hydrogen
bond
target
base
nucleosid
inhibitor
make
key
interact
conserv
glutam
residu
env
motif
motif
iv
arginin
residu
rxr
motif
motif
viii
although
zebularin
form
hydrogen
bond
due
fact
zebularin
lack
amino
group
posit
distanc
suffici
start
catalyt
mechan
addit
zebularin
avail
hydrogen
bond
distanc
proton
fig
observ
agreement
dock
pose
catalyt
site
homolog
model
yoo
medinafranco
homolog
model
nucleosid
inhibitor
make
hydrogen
bond
network
common
key
amino
acid
residu
rmsd
valu
topscor
pose
nucleosid
inhibitor
modifi
crystal
structur
homolog
less
comparison
show
similar
bind
mode
obtain
crystal
structur
model
activ
state
previous
gener
homolog
model
therefor
result
suggest
model
use
score
pose
select
virtual
screen
next
paragraph
describ
detail
bind
mode
repres
inhibitor
catalyt
site
crystal
structur
human
model
activ
conform
hydralazin
antihypertens
drug
antitumor
effect
use
combin
valproic
acid
histon
deacetylas
inhibitor
arc
et
al
et
al
figur
show
comparison
bind
mode
hydralazin
target
cytidin
amino
group
hydralazin
cytidin
match
well
form
hydrogen
bond
nitrogen
phthalazin
ring
overlap
carbonyl
oxygen
form
hydrogen
bond
rxr
motif
similar
bind
mode
hydralazin
low
rmsd
obtain
use
homolog
model
dock
protocol
yoo
medinafranco
accord
bind
pose
small
structur
hydralazin
could
occupi
site
sugar
ring
phosphat
backbon
nucleosid
analogu
therefor
design
analogu
substitut
posit
hydralazin
enhanc
enzymat
affin
yoo
medinafranco
natur
product
epigallocatechin
gallat
egcg
curcumin
parthenolid
mahanin
inhibitor
identifi
virtual
screen
analogu
approv
drug
indic
procain
procainamid
dock
catalyt
bind
site
modifi
crystal
structur
compar
bind
mode
homolog
model
tabl
ii
summar
common
amino
acid
residu
particip
hydrogen
bond
interact
sesquiterpen
lacton
parthenolid
identifi
antiinflammatori
medicin
herb
feverfew
suggest
coval
blocker
previou
dock
studi
homolog
model
support
hypothesi
yoo
medinafranco
bind
pose
modifi
crystal
structur
overlap
previou
dock
model
low
rmsd
make
hydrogen
bond
common
arginin
residu
dock
pose
procain
procainamid
mahanin
two
catalyt
bind
site
show
similar
interact
key
amino
acid
residu
within
rmsd
although
bind
pose
egcg
curcumin
differ
form
hydrogen
bond
common
amino
acid
residu
import
catalyt
mechan
iv
pharmacophor
model
establish
dnmt
inhibitor
fig
develop
energyoptim
pharmacophor
epharmacophor
hypothesi
use
bestscor
pose
compound
descriptor
calcul
glide
xp
employ
structurebas
pharmacophor
approach
previous
use
model
dnmt
inhibitor
use
homolog
model
catalyt
site
yoo
medinafranco
approach
base
map
energet
term
glide
xp
score
function
onto
atom
center
advantag
combin
pharmacophor
percept
proteinligand
energet
term
rank
import
pharmacophor
featur
salam
et
al
dock
model
inhibitor
refin
use
glide
xp
glide
xp
score
term
comput
energi
map
atom
pharmacophor
site
automat
gener
phase
version
llc
new
york
ny
use
default
set
six
chemic
featur
name
hydrogen
bond
acceptor
hydrogen
bond
donor
hydrophob
h
neg
ioniz
n
posit
ioniz
p
aromat
ring
r
site
glide
xp
energi
atom
compris
pharmacophor
site
sum
pharmacophor
site
rank
base
sum
energi
favor
site
select
pharmacophor
hypothesi
salam
featur
use
develop
common
pharmacophor
model
evalu
abil
reproduc
known
inhibitor
use
phase
distanc
match
toler
set
account
protein
flexibl
lessen
effect
minor
steric
clash
exclud
volum
sphere
creat
receptor
atom
within
around
ligand
sphere
radiu
correspond
van
der
waal
radiu
receptor
atom
receptor
atom
less
ligand
ignor
combin
bestscor
featur
match
minimum
two
site
known
inhibitor
chosen
regener
salam
et
al
figur
show
fivefeatur
pharmacophor
model
inhibitor
energet
valu
amino
acid
residu
particip
interact
shown
figur
bestscor
featur
neg
charg
n
close
side
chain
second
third
favor
featur
donor
site
near
side
chain
acceptor
site
close
proxim
side
chain
rxr
motif
fourth
rank
featur
aromat
ring
r
stabil
bind
conform
ligand
adohci
fifth
rank
featur
donor
site
near
side
chain
residu
implic
mechan
methyl
fig
pharmacophor
featur
repres
import
interact
inhibitor
catalyt
site
notabl
glutam
env
motif
arginin
rxr
motif
highli
conserv
residu
catalyt
domain
dnmt
jurkowska
et
al
interestingli
fivefeatur
pharmacophor
model
deriv
modifi
crystal
structur
fig
consist
pharmacophor
hypothesi
previous
report
homolog
model
although
rank
featur
nearbi
amino
acid
slightli
differ
inhibitor
match
sever
pharmacophor
featur
consid
distanc
toler
repres
exampl
shown
fig
e
nucleosid
analogu
except
zebularin
match
five
pharmacophor
featur
fig
c
zebularin
match
four
featur
satisfi
hydrogen
bond
donor
featur
interact
zebularin
amino
group
base
ring
howev
donor
featur
match
proton
form
zebularin
despit
fact
hydralazin
small
structur
match
aromat
ring
r
donor
acceptor
featur
close
fig
agreement
previou
find
model
hydralazin
homolog
model
singh
et
al
yoo
medinafranco
base
result
expect
hydralazin
analogu
match
toprank
neg
charg
featur
n
improv
potenc
suggest
previous
yoo
medinafranco
interestingli
carboxyl
function
group
match
neg
featur
n
indol
ring
structur
satisfi
ring
featur
r
egcg
also
match
four
pharmacophor
featur
hydroxyl
group
ring
b
match
ring
featur
r
acceptor
donor
featur
close
glutam
arginin
residu
keton
gallat
moieti
match
neg
featur
n
curcumin
mahanin
match
aromat
ring
r
donor
featur
nearbi
although
parthenolid
match
acceptor
featur
possibl
gmethylen
lacton
alkyl
catalyt
previous
suggest
liu
et
al
result
similar
insight
previous
report
homolog
model
catalyt
domain
contrast
compound
inact
previous
use
decoy
fig
match
pharmacophor
featur
satisfi
one
featur
even
molecul
carboxyl
group
like
known
inhibitor
match
neg
featur
n
donor
featur
interact
taken
togeth
result
structurebas
pharmacophor
model
modifi
crystal
structur
good
agreement
dock
studi
describ
previous
report
dock
pharmacophor
model
homolog
model
inhibitor
human
well
recogn
integr
comput
experiment
approach
boost
design
novel
enzym
molecular
target
inhibitor
advanc
drug
candid
demonstr
area
inhibitor
exampl
virtual
screen
larg
compound
databas
follow
experiment
character
lead
identif
novel
inhibitor
acid
fig
siedlecki
et
al
kuck
et
al
increas
interest
biolog
activ
acid
relat
compound
exampl
acid
also
emerg
experiment
valid
hit
virtual
screen
viral
rna
methyltransferas
promis
drug
target
flavivirus
caus
agent
sever
diseas
dengu
yellow
fever
podvinec
et
al
addit
separ
virtual
screen
structur
analogu
acid
ata
fig
identifi
potent
inhibitor
methyltransferas
activ
flavivir
methyltransferas
milani
et
al
also
recent
studi
show
ata
inhibit
two
adometdepend
rna
methyltransferas
sever
acut
respiratori
syndrom
sar
coronaviru
bouvet
et
al
recent
studi
show
structur
analogu
ata
fig
inhibitor
yoo
medinafranco
preliminari
dock
studi
ata
homolog
model
strongli
suggest
compound
would
show
enzymat
inhibitori
activ
experiment
test
hypothesi
part
ongo
effort
identifi
novel
inhibitor
conduct
experiment
character
ata
enzymat
inhibitor
use
vitro
assay
order
experiment
test
hypothesi
ata
inhibitor
enzymat
inhibitori
activ
compound
measur
use
nonradioact
vitro
enzymat
assay
assay
fulllength
human
express
baculoviru
infect
insect
cell
h
system
fastbacht
system
invitrogen
hexahistidin
tag
purifi
nickel
nta
resin
describ
previous
yokochi
robertson
dialyz
remov
imidazol
use
colorimetr
dnmt
activ
kit
epigentek
elisalik
assay
use
antibodi
detect
methyl
incub
substrat
plu
minu
inhibitor
sampl
read
plate
reader
nm
determin
activ
figur
illustr
doserespons
plot
rang
concentr
assay
figur
fig
also
show
inhibit
plot
select
inhibitor
use
posit
control
name
sah
natur
product
egcg
ltryptophan
deriv
sah
egcg
show
ic
valu
mm
respect
assay
condit
show
inhibit
mm
figur
show
inhibit
plot
ata
reveal
ic
mm
note
enzymat
inhibitori
activ
ata
greater
activ
sah
compar
activ
egcg
current
assay
condit
also
measur
inhibit
ata
show
ic
mm
fig
indic
ata
somewhat
select
toward
approxim
twofold
order
explor
bind
mode
ata
molecular
level
conduct
molecular
model
ata
dock
ata
crystal
structur
modifi
activ
conform
suggest
two
bind
pose
first
dock
pose
ata
shown
fig
deproton
form
expect
aqueou
solut
accord
bind
model
ata
form
strong
hydrogen
bond
network
amino
acid
residu
interact
nucleosid
inhibitor
hydroxybenzo
acid
moieti
ata
form
hydrogen
fig
titrat
recombin
enzymat
activ
use
colorimetr
assay
activ
measur
use
epiquik
dna
methyltransferas
activ
inhibit
assay
kit
epigentek
bd
doserespons
plot
compound
data
present
term
percentag
activ
versu
result
use
vehicl
treat
control
assign
valu
ic
concentr
compound
determin
enzym
assay
ident
condit
pmol
incub
h
bond
carboxyl
group
make
interact
structur
relat
acid
show
weak
inhibitori
activ
biochem
assay
kuck
et
al
although
bind
pose
partial
overlap
ata
show
interact
make
key
interact
shown
similar
bind
model
also
determin
previou
studi
use
homolog
model
yoo
medinafranco
second
pose
ata
consist
recent
report
bind
mode
catalyt
site
homolog
model
yoo
medinafranco
note
ata
show
good
dock
score
compar
nucleosid
inhibitor
tabl
also
compar
bind
model
ata
obtain
glide
xp
pharmacophor
model
develop
modifi
crystal
structur
fig
bind
posit
ata
match
bestscor
featur
neg
charg
n
hydrogen
bond
acceptor
interact
donor
interact
aromat
ring
r
fig
contrast
satisfi
one
neg
featur
n
therefor
model
suggest
introduct
substitu
could
match
donor
acceptor
featur
associ
interact
glutam
arginin
residu
would
enhanc
affin
analogu
bind
posit
match
three
pharmacophor
featur
neg
charg
n
hydrogen
bond
acceptor
aromat
ring
r
find
support
experiment
observ
analysi
dock
energi
dnmt
involv
epigenet
regul
genom
promis
target
therapeut
intervent
cancer
diseas
comput
approach
increasingli
use
identifi
promis
compound
potenti
therapeut
agent
research
tool
studi
epigenet
mechan
involv
dnmt
also
comput
method
employ
better
understand
mechan
establish
inhibitor
dna
methyl
herein
describ
molecular
model
studi
recent
publish
crystallograph
structur
human
contain
unmethyl
dna
enzym
inact
conform
conform
crystallograph
structur
model
activ
state
use
molecular
dynam
experiment
known
inhibitor
dock
parallel
modifi
crystal
structur
glide
htv
sp
xp
bind
mode
character
common
interact
amino
acid
residu
particip
propos
mechan
dna
key
amino
acid
residu
includ
dock
score
also
abl
distinguish
activ
inhibitor
known
inact
previous
use
decoy
compound
inde
establish
inhibitor
high
rank
score
base
dock
result
structurebas
pharmacophor
model
develop
character
five
featur
includ
neg
charg
aromat
ring
hydrogen
bond
acceptor
two
donor
site
pharmacophor
model
repres
key
proteinligand
interact
inhibitor
obtain
dock
result
dock
pharmacophor
model
good
agreement
insight
model
studi
publish
previous
use
homolog
model
catalyt
domain
part
ongo
interest
identifi
novel
inhibitor
experiment
test
ata
enzymat
inhibit
assay
preliminari
dock
studi
ata
strongli
suggest
structur
analogu
acid
would
show
enzymat
inhibitori
activ
inde
ata
show
ic
mm
human
also
measur
inhibit
ata
show
ic
mm
indic
ata
somewhat
select
toward
approxim
twofold
major
followup
studi
work
perform
virtual
screen
larg
compound
data
set
use
valid
dock
protocol
pharmacophor
model
crystal
structur
human
model
activ
conform
identifi
potenti
novel
inhibitor
order
explor
perhap
someday
enhanc
enzymat
select
toward
murin
current
employ
molecular
dock
model
approach
ata
publish
crystal
structur
jia
et
al
result
insight
molecular
model
publish
separ
commun
due
cours
